S&P 500   3,147.08 (+0.04%)
DOW   27,986.78 (-0.10%)
QQQ   205.46 (+0.22%)
AAPL   269.61 (-0.41%)
FB   202.00 (+0.47%)
MSFT   152.05 (+0.20%)
GOOGL   1,348.92 (+0.71%)
AMZN   1,763.38 (+0.67%)
CGC   20.76 (+11.31%)
NVDA   213.28 (+0.52%)
MU   47.26 (-1.40%)
BABA   202.42 (+0.26%)
GE   11.08 (-0.18%)
TSLA   338.50 (+0.78%)
T   38.33 (+0.34%)
AMD   39.76 (+0.33%)
ACB   2.53 (+4.12%)
F   9.02 (+0.00%)
PRI   134.96 (-0.53%)
NFLX   308.14 (+0.26%)
BAC   33.64 (-0.09%)
GILD   67.32 (+0.36%)
DIS   147.97 (+0.21%)
S&P 500   3,147.08 (+0.04%)
DOW   27,986.78 (-0.10%)
QQQ   205.46 (+0.22%)
AAPL   269.61 (-0.41%)
FB   202.00 (+0.47%)
MSFT   152.05 (+0.20%)
GOOGL   1,348.92 (+0.71%)
AMZN   1,763.38 (+0.67%)
CGC   20.76 (+11.31%)
NVDA   213.28 (+0.52%)
MU   47.26 (-1.40%)
BABA   202.42 (+0.26%)
GE   11.08 (-0.18%)
TSLA   338.50 (+0.78%)
T   38.33 (+0.34%)
AMD   39.76 (+0.33%)
ACB   2.53 (+4.12%)
F   9.02 (+0.00%)
PRI   134.96 (-0.53%)
NFLX   308.14 (+0.26%)
BAC   33.64 (-0.09%)
GILD   67.32 (+0.36%)
DIS   147.97 (+0.21%)
S&P 500   3,147.08 (+0.04%)
DOW   27,986.78 (-0.10%)
QQQ   205.46 (+0.22%)
AAPL   269.61 (-0.41%)
FB   202.00 (+0.47%)
MSFT   152.05 (+0.20%)
GOOGL   1,348.92 (+0.71%)
AMZN   1,763.38 (+0.67%)
CGC   20.76 (+11.31%)
NVDA   213.28 (+0.52%)
MU   47.26 (-1.40%)
BABA   202.42 (+0.26%)
GE   11.08 (-0.18%)
TSLA   338.50 (+0.78%)
T   38.33 (+0.34%)
AMD   39.76 (+0.33%)
ACB   2.53 (+4.12%)
F   9.02 (+0.00%)
PRI   134.96 (-0.53%)
NFLX   308.14 (+0.26%)
BAC   33.64 (-0.09%)
GILD   67.32 (+0.36%)
DIS   147.97 (+0.21%)
S&P 500   3,147.08 (+0.04%)
DOW   27,986.78 (-0.10%)
QQQ   205.46 (+0.22%)
AAPL   269.61 (-0.41%)
FB   202.00 (+0.47%)
MSFT   152.05 (+0.20%)
GOOGL   1,348.92 (+0.71%)
AMZN   1,763.38 (+0.67%)
CGC   20.76 (+11.31%)
NVDA   213.28 (+0.52%)
MU   47.26 (-1.40%)
BABA   202.42 (+0.26%)
GE   11.08 (-0.18%)
TSLA   338.50 (+0.78%)
T   38.33 (+0.34%)
AMD   39.76 (+0.33%)
ACB   2.53 (+4.12%)
F   9.02 (+0.00%)
PRI   134.96 (-0.53%)
NFLX   308.14 (+0.26%)
BAC   33.64 (-0.09%)
GILD   67.32 (+0.36%)
DIS   147.97 (+0.21%)
Log in

NYSEAMERICAN:ARMP - Armata Pharmaceuticals Stock Price, Forecast & News

$4.03
-0.11 (-2.66 %)
(As of 12/9/2019 09:58 AM ET)
Today's Range
$4.00
Now: $4.03
$4.16
50-Day Range N/A
52-Week Range
$2.10
Now: $4.03
$6.23
Volume18,050 shs
Average Volume45,257 shs
Market Capitalization$40.03 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorHealth Technology
Current SymbolNYSEAMERICAN:ARMP
CUSIPN/A
CIKN/A
WebN/A
Phone(310) 655-2928

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$40.03 million
Next Earnings Date3/23/2020 (Estimated)
OptionableNot Optionable

Receive ARMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ARMP and its competitors with MarketBeat's FREE daily newsletter.


Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Frequently Asked Questions

What is Armata Pharmaceuticals' stock symbol?

Armata Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ARMP."

How were Armata Pharmaceuticals' earnings last quarter?

Armata Pharmaceuticals Inc (NYSEAMERICAN:ARMP) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.34. View Armata Pharmaceuticals' Earnings History.

When is Armata Pharmaceuticals' next earnings date?

Armata Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for Armata Pharmaceuticals.

What price target have analysts set for ARMP?

2 analysts have issued 1-year price targets for Armata Pharmaceuticals' stock. Their forecasts range from $9.00 to $9.50. On average, they anticipate Armata Pharmaceuticals' share price to reach $9.25 in the next twelve months. This suggests a possible upside of 129.5% from the stock's current price. View Analyst Price Targets for Armata Pharmaceuticals.

What is the consensus analysts' recommendation for Armata Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Armata Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Armata Pharmaceuticals.

What are Wall Street analysts saying about Armata Pharmaceuticals stock?

Here are some recent quotes from research analysts about Armata Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California. " (11/15/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy and $7 price target. The sole contributor to our valuation, at this point is AB-SA01, with a projected 15% chance of success with $415 million in peak sales off of a 2024 launch. Overall, we believe that our projected chance of success could be considered conservative based on the efficacy and safety profile, to date, in very sick patients, and continues to highlight the valuation disconnect, in our belief. We do not include projections for the P. aeruginosa program, and would look to reevaluate based on visibility on the path forward." (8/15/2019)

Has Armata Pharmaceuticals been receiving favorable news coverage?

Headlines about ARMP stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Armata Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Armata Pharmaceuticals.

Are investors shorting Armata Pharmaceuticals?

Armata Pharmaceuticals saw a drop in short interest in the month of November. As of November 15th, there was short interest totalling 132,600 shares, a drop of 5.2% from the October 31st total of 139,800 shares. Based on an average trading volume of 11,700 shares, the short-interest ratio is presently 11.3 days. Currently, 3.0% of the company's stock are sold short. View Armata Pharmaceuticals' Current Options Chain.

Who are some of Armata Pharmaceuticals' key competitors?

What other stocks do shareholders of Armata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Armata Pharmaceuticals investors own include Aerie Pharmaceuticals (AERI), Antares Pharma (ATRS), Check Cap (CHEK), Sutter Rock Capital (SSSS), GameStop (GME), Freedom (FRHC), American Woodmark (AMWD), Arena Pharmaceuticals (ARNA), Cellectar Biosciences (CLRB) and Columbia Sportswear (COLM).

Who are Armata Pharmaceuticals' key executives?

Armata Pharmaceuticals' management team includes the folowing people:
  • Todd R. Patrick, Chief Executive Officer & Director
  • Brian C. Varnum, President & Chief Development Officer
  • Duane A. Morris, Vice President-Operations
  • Steven Robert Martin, Chief Financial Officer & Head-Media Contacts

Who are Armata Pharmaceuticals' major shareholders?

Armata Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Stifel Financial Corp (0.23%).

Which major investors are buying Armata Pharmaceuticals stock?

ARMP stock was acquired by a variety of institutional investors in the last quarter, including Stifel Financial Corp.

How do I buy shares of Armata Pharmaceuticals?

Shares of ARMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Armata Pharmaceuticals' stock price today?

One share of ARMP stock can currently be purchased for approximately $4.03.

How big of a company is Armata Pharmaceuticals?

Armata Pharmaceuticals has a market capitalization of $40.03 million. View Additional Information About Armata Pharmaceuticals.

How can I contact Armata Pharmaceuticals?

The company can be reached via phone at (310) 655-2928.


MarketBeat Community Rating for Armata Pharmaceuticals (NYSEAMERICAN ARMP)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  16 (Vote Outperform)
Underperform Votes:  13 (Vote Underperform)
Total Votes:  29
MarketBeat's community ratings are surveys of what our community members think about Armata Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel